Literature DB >> 3011151

Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood.

S Rodenhuis, J L Bos, R M Slater, H Behrendt, M van 't Veer, L A Smets.   

Abstract

To examine whether determination of (1) the copynumber or restriction pattern of certain oncogenes or (2) the mutational activation of the N-ras gene might contribute to the risk classification of acute lymphoblastic leukemia of childhood (ALL), we investigated DNA isolated from lymphoblasts of untreated patients. Restriction enzyme analysis of cellular oncogenes was performed on DNA of 25 patients. No rearrangements could be demonstrated within or near the genes c-myc, c-myb, c-abl, bcr, c-Ki-ras, and N-ras. No amplifications of these genes nor of N-myc or c-Ha-ras were present. Eight of 21 patients were heterozygote for "rare" Ha-ras allelic restriction fragments that have been associated with an increased risk of developing a malignancy. These patients were clinically indistinguishable from patients lacking these fragments. The breakpoint cluster region (bcr) that is rearranged in all patients with Philadelphia chromosome positive chronic myeloid leukemia, was normal in all cases, including at least one patient with Philadelphia chromosome positive ALL. A 2.8 kb HindIII fragment of a hitherto unknown gene or pseudogene related to v-myb probably derives from the Y chromosome. Nineteen patients were examined for point mutations in the N-ras gene, using a novel synthetic oligonucleotide hybridization assay. In two patients activating point mutations were present, both in positions 1 of the 12th codon. Both patients were somewhat older than the others (16 and 11 years), had L2 morphology, and were shown to have high growth fractions of tumor in their bone marrow.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011151

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Molecular biology in medicine.

Authors:  B D Young
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

2.  Analysis of RAS oncogene mutations in human lymphoid malignancies.

Authors:  A Neri; D M Knowles; A Greco; F McCormick; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 3.  Genetic and cytogenetic changes in acute lymphoblastic leukemia.

Authors:  H G Ahuja; M J Cline
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2.

Authors:  Kevin S Smith; Joon Whan Rhee; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

5.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Zhongde Wang; Li Xuan Tan; Myung-Jeom Ryu; Benjamin Meline; Juan Du; Ken H Young; Erik Ranheim; Qiang Chang; Jing Zhang
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

6.  E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice.

Authors:  M P Kamps; D Baltimore
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

7.  Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Authors:  Emma M C Driessen; Eddy H J van Roon; Jill A P Spijkers-Hagelstein; Pauline Schneider; Paola de Lorenzo; Maria Grazia Valsecchi; Rob Pieters; Ronald W Stam
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

8.  RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

Authors:  J W Janssen; A C Steenvoorden; J Lyons; B Anger; J U Böhlke; J L Bos; H Seliger; C R Bartram
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  Human hypervariable sequences in risk assessment: rare Ha-ras alleles in cancer patients.

Authors:  T G Krontiris; N A DiMartino; H D Mitcheson; J A Lonergan; C Begg; D R Parkinson
Journal:  Environ Health Perspect       Date:  1987-12       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.